KEY POINTS
- HYPOCON is an investigator-initiated, multicentre, open-label randomized trial designed to test whether a biphasic fractionation strategy is feasible in locally advanced head and neck squamous cell carcinoma. It plans to recruit 46 patients across four centres, randomized 1:1.
- The biological idea is deliberately time-dependent: tumor hypoxia may diminish after approximately 3–4 weeks of fractionated radiotherapy, just as accelerated clonogenic repopulation begins. The investigators therefore propose increasing fraction size late in treatment.
- The control arm receives 55 Gy in 20 fractions over 4 weeks. The experimental arm receives 40 Gy in 20 fractions, followed by a hypofractionated boost of 15 Gy in 3 consecutive daily fractions.
- Both arms receive concurrent intravenous cisplatin. The experimental schedule was modeled to preserve comparable late-tissue biological dose: using an α/β of 3 Gy, BED was 106.67 Gy versus 105.42 Gy with the control regimen, a difference of only 1.18%.
- Eligible patients have locally advanced squamous cell carcinoma treated with definitive chemoradiotherapy; the protocol focuses on patients fit for cisplatin and includes tumors of the oropharynx, hypopharynx and laryngeal region.
- The primary endpoint is feasibility, not tumor control. Secondary endpoints include grade ≥3 acute and late toxicity, response, disease-free survival and overall survival.
- With only 46 participants, the trial is explicitly underpowered to establish efficacy. Its purpose is to determine whether this strategy can be delivered safely and practically before progression to a definitive larger trial.
CLINICAL TAKEAWAY
HYPOCON asks a genuinely interesting radiobiological question: rather than treating hypoxia as static, can fractionation be changed when reoxygenation is expected to have occurred? But this paper provides no clinical result yet. The value of the study will initially be whether the regimen is deliverable and tolerable, not whether it improves control or survival.